Reduction of preoperative fasting time on scheduled cesarean sectio

Not Applicable

• Conditions: Cesarean section; E04.520.252.500; F01.145.407.400; Pregnant women; M01.975.807; Fasting

• Registration Number: RBR-7bn9gc
• Lead Sponsor: Hospital Universitário Julio Müller HUJM

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2019-10-02
• Last Update Posted: 29 May 2023

Recruitment & Eligibility

• Status: ot yet recruiting
• Sex: Female
• Target Recruitment: Not specified

Inclusion Criteria

Women 18 to 40 years of age; above 39 gestational weeks Present body mass index (BMI kg / m²) suitable for gestational age according to the chart of Atalah et al 1997 Single fetus Elective caesarean with wall opening abdominal pain by the Pfannenstiel technique Present ASA (American Society of Anesthesiologist) score I and II Be submitted to the regional anesthetic technique; Ability to understand the rationale of the study evaluations; Signed the free and informed consent form.

Exclusion Criteria

Patients who do not adhere to the protocol at any stage of the study and who present: Anemia (Hb <11.0 g / dL); Gestational Diabetes (Fasting glycemia above 95 mg / dL by the TGO reference value: (> 140/90 mmHg); Renal or hepatic disease; C-reactive protein> 6.0 mg / L; Clinical repercussion of gastroesophageal reflux for the gravidic condition (Hyperemesis gravidarum, abnormal anatomy of the upper gastrointestinal tract); Operating time greater than two hours; Blood collection in the non-scheduled period; Preoperative complications requiring an emergency or major intraoperative cesarean section (eg hemorrhage).

Study & Design

• Study Type: Intervention
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
To attenuate the organic response to elective cesarean section with the ingestion of a liquid formula containing carbohydrate and glutamine;<br><br><br><br><br><br>;Decrease the inflammatory markers PCR and I-6 with variation of at least 5% between the experimental and control groups;;Decrease HOMA-IR (homeostasis model assessment-insulin resistance: glycemia x insulin / 405) with variation of at least 5% between the experimental and control groups;;Maintain the palmar grip strength, measured by the manual dynamometer, noting a difference of at least 5% between the experimental and control groups.

Secondary Outcome Measures

Name	Time	Method
Reduce hunger (self-reported response);Reduce thirst (self-reported response);Avoid hypoglycemia (measured by biochemical blood glucose values) with a difference of at least 5% between groups.